Is buprenorphine “microinduction” a safe and effective method of medication initiation for opioid use disorder?

Abstract

significantly lower in the ulipristal acetate group compared with placebo (7 vs 12 days; P5.002). A significantly more women in the ulipristal acetate group experienced cessation of bleeding within 10 days compared with placebo (34.4% vs 9.7%; P5.03; NNT54). Limitations included the small sample size, possible recall bias in bleeding diary reports before start of trial, and having to end the study early because of FDA recall and concern for possible liver toxicity.